Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) shares were up 5.9% during mid-day trading on Tuesday . The stock traded as high as $58.17 and last traded at $57.40, with a volume of 671,322 shares trading hands. The stock had previously closed at $54.22.

Several research analysts recently issued reports on RARE shares. Canaccord Genuity reaffirmed a “buy” rating on shares of Ultragenyx Pharmaceutical in a research report on Monday, April 4th. Leerink Swann reaffirmed a “buy” rating on shares of Ultragenyx Pharmaceutical in a research report on Thursday, June 16th. Wedbush reaffirmed an “outperform” rating and set a $92.00 target price on shares of Ultragenyx Pharmaceutical in a research report on Tuesday, June 28th. Jefferies Group reaffirmed a “buy” rating and set a $109.00 target price on shares of Ultragenyx Pharmaceutical in a research report on Tuesday, May 10th. Finally, Bank of America Corp. started coverage on Ultragenyx Pharmaceutical in a research report on Tuesday, June 28th. They set a “buy” rating and a $72.00 target price on the stock. Three analysts have rated the stock with a hold rating, fifteen have given a buy rating and one has assigned a strong buy rating to the stock. The company has a consensus rating of “Buy” and a consensus price target of $98.09.

The company’s market cap is $2.23 billion. The company has a 50 day moving average of $55.26 and a 200-day moving average of $62.63.

Ultragenyx Pharmaceutical (NASDAQ:RARE) last posted its quarterly earnings results on Monday, May 9th. The biopharmaceutical company reported ($1.35) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($1.29) by $0.06. During the same period in the previous year, the business posted ($0.63) EPS. The business’s revenue for the quarter was up .0% on a year-over-year basis. On average, equities research analysts predict that Ultragenyx Pharmaceutical Inc. will post ($5.84) EPS for the current year.

In other Ultragenyx Pharmaceutical news, CEO Emil D. Kakkis sold 20,000 shares of Ultragenyx Pharmaceutical stock in a transaction that occurred on Monday, May 16th. The shares were sold at an average price of $59.95, for a total value of $1,199,000.00. Following the transaction, the chief executive officer now owns 526,704 shares in the company, valued at $31,575,904.80. The transaction was disclosed in a document filed with the SEC, which is available at this link. Also, insider Sunil Agarwal sold 649 shares of Ultragenyx Pharmaceutical stock in a transaction that occurred on Thursday, July 21st. The stock was sold at an average price of $52.68, for a total transaction of $34,189.32. The disclosure for this sale can be found here.

A number of hedge funds and institutional investors have bought and sold shares of RARE. Trexquant Investment LP acquired a new position in Ultragenyx Pharmaceutical during the fourth quarter valued at about $1,010,000. GSA Capital Partners LLP raised its position in Ultragenyx Pharmaceutical by 12.2% in the fourth quarter. GSA Capital Partners LLP now owns 11,188 shares of the biopharmaceutical company’s stock worth $1,255,000 after buying an additional 1,218 shares in the last quarter. Russell Frank Co raised its position in Ultragenyx Pharmaceutical by 425.8% in the fourth quarter. Russell Frank Co now owns 13,523 shares of the biopharmaceutical company’s stock worth $1,529,000 after buying an additional 10,951 shares in the last quarter. GAM Holding AG raised its position in Ultragenyx Pharmaceutical by 53.3% in the fourth quarter. GAM Holding AG now owns 32,500 shares of the biopharmaceutical company’s stock worth $3,646,000 after buying an additional 11,300 shares in the last quarter. Finally, Mutual of America Capital Management LLC raised its position in Ultragenyx Pharmaceutical by 1.5% in the fourth quarter. Mutual of America Capital Management LLC now owns 33,497 shares of the biopharmaceutical company’s stock worth $3,758,000 after buying an additional 497 shares in the last quarter.

Ultragenyx Pharmaceutical Inc is a clinical-stage biopharmaceutical company. The Company is focused on the identification, acquisition, development, and commercialization of products for the treatment of genetic diseases. The Company is engaged in the identification, acquisition, development and commercialization of products for the treatment of rare and ultra-rare diseases segment.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.